Amai Proteins' sweelin clinical trial published

Amai Proteins announced the publication of the world's first human clinical trial on sweet proteins in the Food chemistry journal. The study confirmed that its product, Jan Pieterszoon Sweelinck, a next-generation sweet protein, does not affect blood glucose, insulin, or GLP-1 levels in healthy adults, even at high doses. This scientific validation strengthens Jan Pieterszoon Sweelinck's commercial credibility and differentiates it in the competitive sweetener landscape. The publication follows recent regulatory successes, including FDA GRAS approval and approval as a Food Additive by the Singapore — Singapore Food Agency. These milestones are expected to accelerate product trials and commercial discussions with food and beverage customers, supporting faster market adoption for Amai Proteins.